Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data
He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.